BioSpace News Archive

Aytu BioPharma, Inc. today announced that its newly issued US patent No. 11,166,947 for Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablet is now listed in the U.S. Food and Drug Administration (FDA) publication.

BiomX Inc. today announced that the Company will host a conference call and a live audio webcast on Wednesday, March 30th, 2022, at 8:00 a.m. EDT, to report fourth quarter and full year 2021 financial results and provide business updates.

Emmaus Life Sciences, Inc. (OTCQX: EMMA) a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced the approval of its application for marketing authorization of Endari® from the United Arab Emirates (U.A.E.) Ministry of Health after a five-month review of the company’s marketing authorization application.

Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need condition announces today it will host a conference call and live webcast on March 30, 2022, at 4:30 p.m. EST to discuss its fourth quarter 2021 results and provide an update on its clinical pipeline.

Anika Therapeutics, Inc., a global joint preservation company, announced it will showcase its comprehensive joint preservation and restoration product portfolio at the 2022 American Academy of Orthopedic Surgeons Annual Meeting on March 23 - 25 in Chicago, IL.

ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the fourth quarter ended December 31, 2021 and provide a corporate strategic update on Monday, March 28, 2022.

Ocelot Bio , Inc. today announced the close of a $36 million Series A financing led by RA Capital Management, Venrock and Vivo Capital and the appointment of Katherine Vega Stultz, an experienced pharmaceutical and biotech executive, as president and chief executive officer.

MedX Health Corp., a global leader in teledermatology, is pleased to announce that Naman Demaghlatrous has been appointed as the Company’s President and Chief Executive Officer, effective immediately.

KRLS-017 is a reversible small molecule inhibitor of Cyclin Dependent Kinase 7. CDK7 has been implicated as a key regulator of both transcriptional addiction and cell cycle dysregulation in tumors and therefore represents an attractive target for therapeutic intervention across a broad range of solid tumors and hematologic malignancies.

Today, Hinge Health announced the results of the first 12-month outcome study demonstrating the long-term benefits of digital care for chronic musculoskeletal (MSK) pain. The peer-reviewed study, published in BMC Musculoskeletal Disorders, showed that pain was reduced by more than half (51%) and sustained over 12 months among Hinge Health participants.